Fibrobody-drug conjugates:
We unlock the potential of powerful molecules by building them into smart, targeted medicines.
We are the first to use targeted delivery methods to combat fibrosis - a condition that afflicts millions of people worldwide. Our approach towards fibrosis is not only about extending and saving lives, but also about improving quality of life for those suffering fibrotic disease. Many fibrosis patients are young; our aim is to give them the chance to lead a healthy, happy life.
We can selectively deliver proven medicines to fibrotic tissue, in order to selectively de-activate fibrosis-mediating cells.
Our solution harnesses the power of existing medicines by coupling them to in-house developed Fibrobodies™ using our own ‘plug and play’ conjugation technology.
Our Fibrobodies™ and conjugation technology are protected by several patent applications.
Research points to long-term growth in a multitude of fibrotic illnesses.
With an experienced, close-knit scientific team, we are ready to take our solution to the next level. We hold all required knowledge and expertise under one roof - LinXis’ specialists self-manage the entire pharmaceutical development cycle – from Fibrobody-drug conjugate design to preclinical- and clinical development.
LinXis is always open to possibilities that could support our company and our pipeline. Do not hesitate to reach out to us at:
LinXis B.V.
Cronenburg 75
1081 GM Amsterdam
The Netherlands
LinXis is always open to possibilities that could support our company and our pipeline. Do not hesitate to reach out to us at:
Our scientific and technical staff are located in the Amsterdam Imaging Center: an award-winning facility in which all disciplines required for image-guided drug development - from organic tracer chemistry to clinical diagnostics - are unified under one single roof.